NetworkNewsBreaks – Rigel Pharmaceuticals, Inc.’s (NASDAQ: RIGL) Shares Rise on FDA Accepting TAVALISSE™ NDA to Treat Chronic ITP
Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) climbed 17% higher this morning after the company said the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISSE™ in patients with chronic or persistent immune thrombocytopenia (ITP). Data from all studies, such as preclinical evaluation and drug manufacturing data, were included in the NDA submission. Based on the Prescription Drug User Fee Act, Rigel anticipates the action date for the FDA to complete its review will be April 17, 2018. The FDA has previously granted Orphan Drug designation to TAVALISSE™ for the treatment of…